ArticleCommunications health2026
Population-based cohort study of modifiable risk factors for dementia and Alzheimer disease mortality in Spain.
Article in Communications health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Background: Although many modifiable factors are linked to dementia risk, their association with dementia and Alzheimer disease (AD) mortality remains unclear. We aimed to identify late-life modifiable factors associated with these outcomes and assess sex differences. Methods: In the population-based Neurological Disorders in Central Spain (NEDICES) cohort, we followed 3085 older adults enrolled in 1994-1995 through 2017. We examined 13 modifiable factors measured at study entry. Dementia and AD deaths were defined by the underlying cause recorded on death certificates. Fine-Gray competing risk models accounted for death from other causes and generated subdistribution hazard ratio (SHR) estimates and adjusted population attributable fractions (PAFs). Results: During follow-up, there were 182 dementia-coded deaths (including 105 AD-coded deaths) and 2423 deaths from other causes. Here we show that depressive symptoms are associated with higher dementia-coded mortality in women (SHR 1.52, 95% confidence interval [CI] 1.00-2.30; PAF 13.6%, 95% CI 0.0-28.4) and higher AD-coded mortality overall (SHR 1.76, 95% CI 1.11-2.79; PAF 15.4%, 95% CI 2.6-29.9), with a stronger association in women (SHR 2.23, 95% CI 1.28-3.88; PAF 27.2%, 95% CI 7.8-46.7). Several exposures show inverse associations (e.g., smoking, obesity, and arterial hypertension in men), consistent with competing mortality and late-life reverse causation. Combined positive PAFs are 10.8% for dementia-coded mortality and 18.2% for AD-coded mortality overall, reaching 41.1% in women for AD-coded mortality. Conclusions: Late-life depressive symptoms, particularly among women, emerged as the most prominent modifiable correlate of dementia- and AD-coded mortality, supporting improved recognition and management of depressive symptoms in older adults.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.